Pharma Pushback on Pricing; Fatal Screening Exclusion; Good News for Kidney Cancer

In an open letter to Congress, pharmaceutical companies said that allowing Medicare to negotiate drug prices “would threaten patients’ access to medicines and sacrifice future medical advances,” lobbying group PhRMA announced. The PD-1 inhibitor camrelizumab joined other drugs in the class in producing a beneficial effect in advanced/metastatic esophageal cancer .

Read the source article at Medical News
2021-09-16 06:00:00